New antibody drug targets deadly heart shock in early trial

NCT ID NCT06832722

Recruiting now Disease control Sponsor: 4TEEN4 Pharmaceuticals GmbH Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 4 times

Summary

This early-stage trial tests a new antibody drug called procizumab in 130 people with cardiogenic shock, a life-threatening condition where the heart cannot pump enough blood. The drug blocks a protein called DPP3, which is linked to worse outcomes. The main goal is to check safety and find the right dose, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: procizumab (also called invobenitug or AK1967), a monoclonal antibody
What this could lead to: If it works, this could point toward a new treatment for cardiogenic shock, a life-threatening condition with few options.
What could go wrong: This is an early phase 1b/2a trial with only 130 participants, so it is primarily testing safety and dosing. The drug may not improve survival or heart function, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SHOCK, CARDIOGENIC

Contacts and locations

Locations

Charles University Motol University Hospital
RECRUITING

Prague, Czechia
Clinical Center Niš
NOT_YET_RECRUITING

Niš, Serbia
Clinical Hospital Center Bezanijska Kosa
NOT_YET_RECRUITING

Belgrade, Serbia
Clinical University Hospital Poznań
RECRUITING

Poznan, Poland
Département d'anesthésie-réanimation
NOT_YET_RECRUITING

Dijon, 21000, France
Erebouni Mwdical Center
NOT_YET_RECRUITING

Yerevan, 0087, Armenia
General University Hospital in Prague - FVN
RECRUITING

Prague, Czechia
Ghent University Hospital
NOT_YET_RECRUITING

Ghent, Belgium
Górnośląskie Centrum Medyczne w Katowicach / Śląski Uniwersytet Medyczny w Katowicach
RECRUITING

Katowice, Poland
Heart Center Aalst, AZORG
RECRUITING

Aalst, Belgium
Hôpital Pitié Salpêtrière
NOT_YET_RECRUITING

Paris, 75651, France
Institute for Cardiovascular Diseases of Vojvodina
NOT_YET_RECRUITING

Kamenitz, Serbia
Institute of Clinical and Experimental Medicine - IKEM
RECRUITING

Prague, Czechia
J. Mikulicz Radecki Clinical University Hospital Wrocław
RECRUITING

Wroclaw, Poland
Lariboisière Hospital AP-HP
RECRUITING

Paris, France
Radboud University Medical Center
RECRUITING

Nijmegen, Netherlands
Regional University Hospital Nancy - Hopitaux de Brabois
RECRUITING

Nancy, France
Uniersytecki Szpital Kliniczny w Białystoku
RECRUITING

Bialystok, Poland
University Hospital - Dupuytren Limoges
RECRUITING

Limoges, France
University Hospital Avicenne AP-HP
RECRUITING

Bobigny, France
University Hospital Lille - Institut Cœur Poumon
RECRUITING

Lille, France
University Hospital Saint Pierre
RECRUITING

Brussels, Belgium
University Hospital and Medical Faculty of Pilsen
RECRUITING

Pilsen, Czechia
Uniwersytecki Szpital Kliniczny w Białymstoku
NOT_YET_RECRUITING

Bialystok, Poland
Yerevan medical scientific center
NOT_YET_RECRUITING

Yerevan, 0014, Armenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.